文献速递炎症性肠病

维多珠单抗治疗炎症性肠病三年有效性与安全性:前瞻性多中心队列研究

Three-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multi-centre cohort study.
PubMed 文献 · Aliment Pharmacol Ther · 2019-06-05

该前瞻性多中心队列研究评估了维多珠单抗治疗克罗恩病(CD)和溃疡性结肠炎(UC)至162周的有效性与安全性。第162周无激素临床缓解率CD为19.9%、UC为36.1%;CD和UC的3年持续用药率分别为26.3%和42.9%;未发现新的安全性信号。

要点

  • 第162周无激素临床缓解率CD为19.9%,UC为36.1%。
  • CD的1、2、3年持续用药率为48.5%、31.4%、26.3%;UC为61.0%、49.9%、42.9%。
  • 因应答丧失而停药者每年约10%,未发现新的安全性信号。

核心结论

  • 维多珠单抗能够维持UC和CD患者的无激素临床缓解至第162周。
  • 因应答丧失导致停用维多珠单抗者每年约10%。

研究设计与样本

  • 前瞻性多中心队列研究,2014年6月至12月共294例患者接受维多珠单抗诱导治疗,其中CD 173例、UC 121例。
  • 149例(CD 78例、UC 71例)在54周后继续接受维多珠单抗治疗。
  • 疾病活动度采用Harvey-Bradshaw指数(CD)和部分Mayo临床评分(UC)评估。
  • 主要结局为第162周无激素临床缓解率,按第0周纳入的全人群计算。

主要发现

  • 第162周无激素临床缓解率CD为19.9%,UC为36.1%。
  • 维多珠单抗剂量优化至300 mg每4周(而非300 mg每8周)由研究者决定,CD中占58.7%,UC中占52.1%。
  • CD的1、2、3年持续用药率分别为48.5%、31.4%、26.3%;UC分别为61.0%、49.9%、42.9%。
  • 未发现新的安全性信号。

临床怎么用

  • 维多珠单抗可用于维持UC和CD患者的无激素临床缓解至第162周。
  • 因应答丧失导致停药者每年约10%。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Cohort studies have described the short-term effectiveness and safety of vedolizumab in treating patients with Crohn's disease (CD) and ulcerative colitis (UC), but data beyond 1 year are lacking. AIM: To assess the effectiveness and safety of vedolizumab after 162 weeks in patients with UC and CD. METHODS: Between June and December 2014, 294 patients including 173 patients with CD and 121 with UC were treated with vedolizumab induction therapy. Among them, 149 continued to be treated with vedolizumab beyond week 54 (78 patients with CD and 71 with UC). Disease activity was assessed using the Harvey-Bradshaw Index for CD and the partial Mayo Clinic score for UC. The primary outcome was steroid-free clinical remission at week 162, computed for the whole population included at week 0. RESULTS: Steroid-free clinical remission rates at week 162 were 19.9% and 36.1% in patients with CD and UC respectively. Vedolizumab dose optimisation to 300 mg every 4 weeks instead of 300 mg every 8 weeks was at investigator's discretion and occurred in 58.7% and 52.1% of patients with CD and UC respectively. The 1-, 2- and 3-year persistence rates of vedolizumab were 48.5%, 31.4% and 26.3% respectively, in patients with CD and 61.0%, 49.9% and 42.9% respectively, in patients with UC. No new safety signal was identified. CONCLUSION: Vedolizumab is able to maintain steroid-free clinical remission in patients with UC and CD up to week 162. Loss of response resulting in discontinuation of vedolizumab occurred in 10% of patients per year.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Amiot A, Serrero M, Peyrin-Biroulet L, et al. Three-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multi-centre cohort study. Aliment Pharmacol Ther. 2019. PMID: 31165509. doi:10.1111/apt.15294

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。